Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis

Status Completed

Clinical Trial Summary

Fractalkine (FKN) is a chemoattractant and adhesion molecule for leukocytes. Angiogenic effect of FKN also has been reported. We investigate FKN-mediated angiogenesis in ocular angiogenic disorders.

Clinical Trial Description

Fractalkine (FKN), the sole member of the CX3C chemokine family, is named for its fractal geometry. The CX3C motif, with three amino acids between the two terminal cysteines, makes fractalkine distinct from other chemokines.The structure of fractalkine, a membrane-bound glycoprotein with the chemokines domain atop an extended mucin-like stalk, also is unique.Membrane-bound FKN can be markedly induced on primary endothelial cells by inflammatory cytokines; this form promotes the robust adhesion of monocytes and T lymphocytes. Soluble FKN can be released by proteolysis at an efficient chemotactic activity level for monocytes and T cells. Thus, FKN is a versatile molecule regulating both cell-cell interactions in its membrane-bound form and directed-cell migration in its soluble form. The receptor of FKN, CXC3R1, is a G protein-couple protein, which expresses T lymphocytes, monocytes, natural killer (NK) cells, microglia, and neurons.Sulfation of tyrosine enhances the function of CX3CR1 in cell capture and firm adhesion. Fractalkine is expressed constitutively in the kidney, heart, lung, and brain. Fractalkine has demonstrated an important role in CNS inflammation, cardiac allograft rejection, arteriogenesis, renal disease, psoriasis, and during pregnancy. Silverman et al demonstrated the presence of FKN in normal cultured microvascular endothelial and stromal cells of iris and retina in vitro. Upon inflammatory cytokine stimulation, EC also express FKN and its receptors with FKN secretion in an autocrine manner. In addition to EC chemotaxis and tube formation, FKN is an angiogenic mediator in rheumatoid arthritis. Therefore, we hypothesize that FKN not only participates in ocular inflammatory reactions, but also plays an important role in ocular angiogenesis. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Angiogenesis
Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Retinal Diseases

Clinical Trial Details

NCT number	NCT00728598
Study type	Observational
Source	National Taiwan University Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 1998
Completion date	December 1998

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01921192` - Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy	Phase 4
Recruiting	`NCT01044875` - Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy	N/A
Active, not recruiting	`NCT00993525` - Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)	Phase 1/Phase 2
Completed	`NCT01307072` - Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy	N/A
Completed	`NCT01758757` - Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy	N/A
Completed	`NCT00600236` - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population	Phase 3
Completed	`NCT05414149` - Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy	N/A
Completed	`NCT05408416` - Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR	N/A
Not yet recruiting	`NCT04464694` - Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema	Phase 4
Not yet recruiting	`NCT03633266` - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy	N/A
Completed	`NCT03490318` - Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
Completed	`NCT01627977` - Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy	Phase 3
Completed	`NCT00776763` - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab	Phase 2
Recruiting	`NCT00563043` - Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment	Phase 4
Completed	`NCT00682240` - Morphological and Functional Retinal Changes Following Retinal Photocoagulation	Phase 4
Completed	`NCT00446381` - Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)	N/A
Completed	`NCT02879422` - Genetic Markers and Proliferative Diabetic Retinopathy	N/A
Enrolling by invitation	`NCT02911311` - Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy	N/A
Recruiting	`NCT05514925` - Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy	Phase 4
Completed	`NCT02858076` - Anti-VEGF vs. Prompt Vitrectomy for VH From PDR	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.